Horizon Discovery – Placing to raise approximately £25 million to accelerate the Company’s growth strategy
Horizon Discovery Group plc (LSE:HZD), the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, is pleased to announce a conditional non-pre-emptive placing of 13,157,895 New Placing Shares… Read More
Parkwalk closes PhoreMost investment
We are pleased to announce that the University of Cambridge Enterprise Fund III has made an investment in PhoreMost as part of a £4m series ‘A’ round of equity and grant funding, of which the equity tranche was… Read More
Horizon Discovery – Positive Trading Update
Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering Cambridge, UK – 19th January 2014: Horizon Discovery Group plc (LSE: HZD) (“Horizon” or the… Read More
FT: Fluidic Analytics develops tools to warn of diseases
Imagine if a simple pinprick blood test could tell if you were in the early stages of Alzheimer’s or heart disease. This is the vision behind Fluidic Analytics, spun out of Cambridge university, which is developing tools to… Read More
Fluidic Analytics – University of Cambridge Enterprise Fund II and Parkwalk investment
Parkwalk have recently closed an investment in Fluidic Analytics for the University of Cambridge Enterprise Fund II and Parkwalk Funds. Fluidic Analytics is developing a line of tools for the rapid, accurate, cost-effective analysis of proteins and other biomolecular species. By combining… Read More
Horizon Discovery – acquires Sage Labs Inc. for $48M
Acquisition makes Horizon the world’s leading gene-editing and translational genomics company Highlights · Horizon acquires Sage Labs Inc. for up to $48M (£29M) comprising up to $16M in cash and up to $32M in new ordinary shares · Acquisition creates a… Read More
Horizon Discovery – Interim Results
Interim Results in-line and Panmure reaffirms ‘Buy Rating’: Interim Results for the Six Months Ended 30 June 2014 Horizon Reports a Strong First Half Positioning the Company for Continued Growth Cambridge, UK, 23 September 2014: Horizon Discovery Group… Read More
DefiniGEN Joins EBiSC Consortium
DefiniGEN (an investment in the University of Cambridge Enterprise Funds I & II), a leading provider of stem cell life science products and services has joined the European Bank for induced pluripotent stem cells (EBiSC) consortium. The consortium… Read More
Horizon Discovery – wins European Mediscience’s Emerging Star Award 2014
Horizon Discovery Group plc, the international life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, is delighted to announce that it has won the “Emerging Star” category at last… Read More
Sphere Fluidics – Parkwalk closes further funding round
We have closed an investment, in the first tranche of a financing round of up to £2m, in Sphere Fluidics for the University of Cambridge Enterprise Fund II and the final investment for Parkwalk Fund IV. This follows the UoCEF I… Read More
Horizon Discovery Says It Has Continued To Trade Strongly Since IPO
Horizon Discovery Group PLC said Wednesday that it had continued to trade strongly since its initial public offering. The company said it had traded “at least in line with expectations”, and that it is pursuing its strategy to… Read More
Omega Diagnostics – Trading Update
Trading Update and Notice of Results Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that results for the year to 31 March 2014 will be in line with market expectations. Revenues… Read More
Horizon Discovery – Record AIM $113m IPO
Parkwalk portfolio company Horizon Discovery is set to create UK stock market history with a significantly oversubscribed AIM IPO on Thursday March 27, with a market cap of £120.5 million after raising £68.6m from institutional investors against an original target… Read More
Horizon – Intention to float on AIM
Horizon Discovery Group plc Announces Intention to Float THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED… Read More
Omega Diagnostics
CD4 Update – Successful completion of Technology Transfer – Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the successful completion of its CD4 technology transfer project with first in-field evaluations to… Read More
Horizon Discovery
Appointment of Chairman – Horizon Discovery has appointed Dr. Ian Gilham as Chairman of its Board of Directors. Dr. Gilham’s healthcare industry career spans thirty years encompassing all aspects of successful company growth and development. He was Chief Executive… Read More
Horizon Discovery
Horizon Discovery Signs Large-Scale License Agreement for its X-MAN Cell Lines in Japan Agreement covers use of 250 of Horizon’s X-MAN genetically defined isogenic cell lines Cambridge, UK, 30 January 2014: Horizon Discovery™ (Horizon), a leading provider of research… Read More
Horizon Discovery
Jan 7 (Reuters) – Horizon Discovery: * Horizon discovery and Astrazeneca have entered into a research, collaboration and license agreement * Agreement to explore a range of oncology-relevant genotypes * Will receive an undisclosed upfront payment * Eligible… Read More
Omega Diagnostics
positive CD4 batch results
DefiniGEN
Parkwalk closes DefiniGEN investment for the University of Cambridge Enterprise Fund II DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology. The Company provides human cells… Read More
